Quick Answer
Cartesian Therapeutics, Inc. reported Research And Development Expense of $58.03 million for the year ending 2025.
- Cartesian Therapeutics, Inc. showed an increase of +28.7% in Research And Development Expense from 2024 to 2025.
- This data is from Cartesian Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Cartesian Therapeutics, Inc.'s Research And Development Expense has grown by 453.4%.
- Historical annual values: Fiscal year 2025: $58.03 million | Fiscal year 2024: $45.11 million | Fiscal year 2023: $71.26 million | Fiscal year 2022: $72.38 million | Fiscal year 2021: $68.74 million | Fiscal year 2020: $54.51 million | Fiscal year 2019: $42.74 million | Fiscal year 2018: $47.69 million | Fiscal year 2017: $45.17 million | Fiscal year 2016: $29.70 million | Fiscal year 2015: $22.98 million | Fiscal year 2014: $10.49 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: